Bempedoic Acid + Ezetimibe Fixed-Dose Combination (FDC) Study in Patients With Type 2 Diabetes and Elevated LDL-C
A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 242 participants.
Also called NCT03531905
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; triple masking; primary purpose treatment
- Phase
- Phase 2
- Enrolled
- 242 participants
- Sponsor
- Registry
-
NCT03531905
-
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- United States
- Registry status
- Completed
Technical summary
Registry record NCT03531905. Randomized; triple masking; primary purpose treatment. Start 2018-05-09 (actual); primary completion 2019-06-18 (actual). Results posted on 2020-04-09.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Bempedoic Acid + Ezetimibe Fixed-Dose Combination (FDC) Study in Patients With Type 2 Diabetes and Elevated LDL-C
- Condition
- Diabetes
- Condition
- Diabetes Mellitus, Type 2
- Condition
- Cholesterolemia
- Intervention (Drug)
- Bempedoic acid + Ezetimibe FDC Oral Tablet
- Intervention (Drug)
- Ezetimibe 10 mg Oral Tablet
- Intervention (Drug)
- Placebo Oral Tablet
- Intervention (Drug)
- Placebo oral capsule
- Lead sponsor
- Esperion Therapeutics, Inc.
Record details
- Record id
cardio:ct-nct03531905- Content hash
79aff5ece583e255b3386b206bdac849e188c90766c92d499c04bbf29c4b66d6